阿福他酶α在中国上市了吗?好购买吗？

Afotalase α is an enzyme replacement therapy drug used to treat hypophosphatasia. It is developed by Alexion Pharmaceuticals of the United States and its trade name is Strensiq. As of July 2025, the drug has not been officially approved for marketing in mainland China, and patients need to purchase it through overseas channels or special channels. Currently, some domestic medical institutions are conducting clinical trials of aftase α, and eligible patients can apply to participate. Since the drug is not included in the national medical insurance, patients need to bear the high cost of treatment at their own expense. The price of 18mg/0.45mL/box is approximately US$13,205.

Is aftase α available on the market in China

As a specific drug for the treatment of the rare disease hypophosphatasia, its domestic launch has attracted much attention. Currently, the drug has not been officially approved in mainland China, and patient access is limited.

Domestic approval status

As of July 2025, aftase α is still in the domestic clinical research stage and has not yet received marketing approval from the National Medical Products Administration (NMPA). Many domestic medical institutions are conducting relevant clinical trials to evaluate its efficacy and safety in Chinese patients.

Temporary import possibility

Some hospitals may provide aftase alpha to urgently needed patients through "temporary import", but strict conditions must be met, including diagnosis certificate, doctor application and hospital approval. This method is complex and expensive.

Opportunities to participate in clinical trials

Some domestic medical institutions are conducting clinical trials of aftase alpha. Eligible patients can apply to participate and receive free drug treatment. This method needs to meet strict admissions criteria.

Afotalase α has not yet been officially launched in China, but patients can obtain treatment opportunities through clinical trials or special import channels.

Is aftase α easy to buy?

Since aftase α has not yet been officially launched in China, patients need to obtain it through special channels, which makes purchasing difficult and risky.

Purchase in regular overseas pharmacies

Patients can go to regular hospitals or pharmacies in countries where aftase α has been marketed (such as the United States, Japan, and some European countries) to purchase it with a doctor's prescription. This method has a reliable source of medicines, but international travel or mailing costs are incurred.

Medical service institutions

Some qualified international medical service institutions can provide aftase alpha purchase services. The qualifications of the platform must be verified to ensure the authenticity of the drug.

Purchase risks in online pharmacies

Nationally certified online drugstore platforms may provide aftase alpha purchase services, but the platform qualifications need to be carefully verified to avoid purchasing counterfeit products. Patients should upload the electronic prescription and complete the purchase after review.

When purchasing aftase alpha, you must carefully choose formal channels and use it under the guidance of a doctor to reduce the risk of medication.

Is aftase α included in the national medical insurance?

As a rare disease treatment drug, aftase α’s medical insurance reimbursement directly affects the patient’s economic burden and treatment accessibility.

Current medical insurance coverage

As of July 2025, aftase α has not yet been included in the national medical insurance catalog, and patients must bear the full cost of treatment out of their own pocket.

Prospects for future inclusion in medical insurance

With the increasing emphasis on rare diseases in China, aftase α is expected to be included in medical insurance or special drug protection mechanisms in the future. Patients can pay attention to relevant policy developments and strive for more medical protection.

Afotalase α is currently not included in the national medical insurance, and patients need to bear the high cost of treatment at their own expense. It is expected that future medical insurance policies will cover such rare disease drugs.